Amgen
AMGN
$3.34 (1.09%)
1D
1W
3M
1Y
5Y
ALL
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
InvestorPlace • 1 hours ago • AMGN
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025InvestorPlace • 5 hours ago • AMGN
Sector Superstars: 3 Stocks Generating the Most Buzz on Wall StreetForbes • 1 day ago • AMGN
Will Amgen Stock Continue To See Higher Levels Driven By Its Obesity Injection?InvestorPlace • 2 days ago • AMGN
3 Tried and True Dividend Stocks to Buy for Your PortfolioCNBC • 2 days ago • AMGN
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominanceCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.